Nautilus Biotechnology (NAUT) Accounts Payables (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Accounts Payables of $1.1 million for Q2 2026, down 7.67% sequentially from $1.2 million in Q1 2026, and up 12.42% YoY from $974000.0 in Q2 2025.
Nautilus Biotechnology (NAUT) Accounts Payables (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Accounts Payables for 7 years, with the latest figure at $1.1 million in Q2 2026.
- Quarterly Accounts Payables rose 12.42% year-over-year to $1.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.1 million (up 12.42% YoY) and the FY2025 annual result came in at $943000.0, down 4.46% from the prior year.
- Accounts Payables retreated to $1.1 million in Q2 2026 per NAUT's latest filing, from $1.2 million in the prior quarter.
- Over five years, Accounts Payables peaked at $1.9 million in Q1 2024 and troughed at $823000.0 in Q3 2022.
- A 5-year average of $1.2 million and a median of $1.2 million in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables jumped 1172.82% in 2022, then plunged 54.78% in 2025.
- Over 5 years, Accounts Payables stood at $1.3 million in 2022, then grew by 28.85% to $1.6 million in 2023, then slumped by 39.78% to $987000.0 in 2024, then fell by 4.46% to $943000.0 in 2025, then increased by 16.12% to $1.1 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.1 million, $1.2 million, and $943000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Mn |
| Mar 31, 2026 | 1.19 Mn |
| Dec 31, 2025 | 943,000.00 |
| Sep 30, 2025 | 893,000.00 |
| Jun 30, 2025 | 974,000.00 |
| Mar 31, 2025 | 841,000.00 |
| Dec 31, 2024 | 987,000.00 |
| Sep 30, 2024 | 1.49 Mn |
| Jun 30, 2024 | 1.63 Mn |
| Mar 31, 2024 | 1.86 Mn |
| Dec 31, 2023 | 1.64 Mn |
| Sep 30, 2023 | 1.14 Mn |
| Jun 30, 2023 | 1.22 Mn |
| Mar 31, 2023 | 1.27 Mn |
| Dec 31, 2022 | 1.27 Mn |
| Sep 30, 2022 | 823,000.00 |
| Jun 30, 2022 | 1.43 Mn |
| Mar 31, 2022 | 1.49 Mn |
| Dec 31, 2021 | 1.72 Mn |
| Sep 30, 2021 | 1.50 Mn |